Glenmark Pharmaceuticals Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a dermatological treatment that is bioequivalent and therapeutically equivalent to Evoclin® Foam, 1% by Mylan Pharmaceuticals Inc. This launch reinforces Glenmark’s commitment to expanding its dermatology portfolio in the United States.
According to IQVIA sales data, the Evoclin® Foam, 1% market recorded annual sales of approximately $5.8 million for the 12-month period ending December 2024. Glenmark’s introduction of the generic version is expected to offer a cost-effective alternative to patients and healthcare providers.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company with a strong presence in Branded, Generics, and OTC segments. The company specializes in respiratory, dermatology, and oncology therapies and operates 11 world-class manufacturing facilities across four continents, catering to over 80 countries.
Ranked among the Top 100 biopharmaceutical companies globally by Pharmaceutical Sales in 2023, Glenmark is also recognized among the Top 50 Generics and Biosimilar companies in 2024 by Generics Bulletin. The company has also made significant strides in sustainability, with its Greenhouse Gas (GHG) emission reduction targets approved by the Science Based Target initiative (SBTi), making it the second pharmaceutical company in India to achieve this milestone.
With this latest launch, Glenmark continues its mission to provide affordable and high-quality medicines while strengthening its foothold in the U.S. dermatology market.
